Relevant bibliographies by topics / Prostate – Cancer – Treatment

Academic literature on the topic 'Prostate – Cancer – Treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Prostate – Cancer – Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Prostate – Cancer – Treatment"

1

Scardino, Peter T. "IL3 Surgical Treatment for Localized Prostate Cancer(IL)." Japanese Journal of Urology 97, no. 2 (2006): 86. http://dx.doi.org/10.5980/jpnjurol.97.86.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vojinov, Sasa, Goran Marusic, Ivan Levakov, and Jelena Popadic-Gacesa. "Influence of hormonal therapy on the level of prostate specific antigen in patients with advanced prostatic cancer." Medical review 63, no. 7-8 (2010): 479–82. http://dx.doi.org/10.2298/mpns1008479v.

Full text
Abstract:
% Karcinomi prostate % Antagonisti androgena % Kastracija % Testosteron % Luteinizirajuci hormone AB Introduction. The aim of this study was to investigate the influence of androgen blockades on prostate specific antigen (PSA) values in patients with locally advanced and metastatic prostatic cancer. Material and methods. The research was conducted on 60 patients. The group of 45 patients with prostatic cancer was divided into 3 subgroups, based on the type of the applied treatment protocol (15 patients on monotherapy with luteinizing hormone-releasing hormone agonists, 15 patients on total androgen blockade and 15 patients on monotherapy with antiandrogen). The control group consisted of 15 patients with benign prostatic hyperplasia. For all patients, the values of testosteron, luteinizing hormone and prostate specific antigen were monitored before as well as after 3 and 6 months during the treatment protocol. Results. All types of the applied treatment protocols in the therapy of prostatic cancer decreased the values of prostate specific antigen significantly The application of total androgen blockade and monotherapy with luteinizing hormone-releasing hormone agonists decreased the levels of prostate specific antigen significantly in comparison with monotherapy with antiandrogen. Conclusion. Although prostate specific antigen is not a prostatic cancer specific parameter, the dynamics of its decrease during the therapy of androgen blockade represents a significant marker of the therapy effect. Cilj rada je bio da se ispita uticaj androgenih blokada na vrednosti prostata specificnog antigena kod bolesnika sa lokalno uznapredovalim i metastatskim karcinomom prostate. Ispitivani uzorak se sastojao od 60 bolesnika. Grupa od 45 bolesnika sa karcinomom prostate bila je podeljena na tri podgrupe, u zavisnosti od primenjenog terapijskog protokola (15 bolesnika na monoterapiji agonistima luteinizirajuceg rilizing hormona, 15 bolesnika na totalnoj androgenoj blokadi i 15 bolesnika na monoterapiji antindrogenom). Kontrolnu grupu cinilo je 15 pacijenata sa benignom hiperplazijom prostate. Svim pacijentima su pracene vrednosti testosterona, luteinizirajuceg hormona i prostata specificnog antigena neposredno pre, kao i tri, to jest sest meseci nakon uvodjenja odgovarajuceg protokola. Sve tri vrste primenjenih terapijskih protokola u lecenju karcinoma prostate statisticki su znatno snizavale vrednosti prostata specificnog antigena u odnosu na pocetne vrednosti. Primena totalne androgene blokade i monoterapije agonistima luteinizirajuceg rilizing hormona dovela je do statisticki znatnog snizenja vrednosti prostata specificnog antigena u poredjenju sa monoterapijom antiandrogenom. Iako prostata specificni antigen nije specifican marker za karcinom prostate, dinamika njegove promene u toku androgene blokade predstavlja bitan pokazatelj terapijskog efekta.
APA, Harvard, Vancouver, ISO, and other styles
3

Ulys, Albertas, Alvydas Vėželis, Andrius Ivanauskas, and Marius Snicorius. "Treatment methods of prostate cancer recurrence after radiotherapy. Current treatment alternatives and our clinical experience." Lietuvos chirurgija 12, no. 3 (January 1, 2013): 138–43. http://dx.doi.org/10.15388/lietchirur.2013.3.1840.

Full text
Abstract:
Background / objectiveProstate cancer is the most common cancer among men of Lithuania. Every year about 3000 new cases of prostate cancer are diagnosed in our country. Many patients receive radiotherapy as primary treatment. Unfortunately, after several years some of the patients are diagnosed with prostate cancer recurrence. These cases are more challenging and require to apply salvage treatment methods. The aim of this article is to present our clinical experience and discuss the main features, advantages and disadvantages of the treatment methods.Patients and methodsRetrospective analysis of 10 salvage prostate cancer recurrence treatment cases was completed. All patients previously received radiotherapy as primary treatment. 5 patients received salvage high- dose brachiterapy (group 1) and other 5- salvage cryotherapy (group 2). Prostate cancer recurrences were diagnosed by multiparametric MRI and ultrasound guided transrectal or transperineal biopsies.ResultsAverage patient age was 64,2±7,9 years in group 1 and 68±3,1 years in group 2. None of the patients had prostate cancer progression to lymph nodes (N) or metastases (M) on initial diagnosis or before salvage treatment. No intraoperative complications were observed. Average time between radiotherapy and salvage therapy in both groups was 88,9±30,1 months. In both groups 1 patient suffered from salvage treatment failure- prostate cancer progression was observed.ConclusionsCurrently there is no perfect treatment method for recurrent prostate cancer. Every situation requires universal aproach. Our initial experience shows that salvage cryotherapy and brachiterapy can be a viable alternative for patients with disease progression after radiotherapy.Key words: prostate cancer, prostate cancer recurrence, salvage treatment.Prostatos vėžio recidyvų po spindulinės terapijos gydymo metodaiŠiuolaikinėje medicinoje naudojami metodai ir mūsų klinikinė patirtis Įvadas / tikslasLietuvoje kasmet nustatoma apie 3000 naujų prostatos vėžio atvejų. Daugeliui pacientų taikomas spindulinis gydymas. Deja, praėjus keletui metų, kai kuriems pacientams diagnozuojamas prostatos vėžio recidyvavimas. Šiuo metu yra daug gydymometodų, bet dažnai iškyla problemų pasirenkant optimalų. Šio straipsnio tikslas – pasidalinti mūsų klinikine patirtimi bei apžvelgti prostatos vėžio recidyvų po spindulinės terapijos gydymo alternatyvas.Pacientai ir metodaiRetrospektyviai buvo išanalizuota dešimt pacientų, kuriems po pirminio gydymo radioterapija buvo diagnozuotas prostatos vėžio recidyvavimas. 5 pacientai buvo gydomi didelių dozių brachiterapija (1 grupė), o likusiems 5 buvo skirta krioterapija(2 grupė). Prostatos vėžio recidyvai diagnozuoti multiparametriniu kontroliuojant MRT ir ultragarsu atliktomis transrektalinėmis ir transperinealinėmis prostatos biopsijomis.RezultataiPirmoje grupėje vidutinis pacientų amžius buvo 64,2±7,9 metų, o antroje grupėje 68±3,1. Nė vienam pacientui nebuvo nustatytas prostatos vėžio išplitimas į limfmazgius (N) ar metastazavimas (M). Intraoperacinių komplikacijų nepasitaikė. Vidutiniškaitarp pirminės radioterapijos ir gelbstinčio prostatos vėžio recidyvavimo gydymo praėjo 88,9±30,1 mėnesio. Gelbstintis prostatos vėžio recidyvavimo gydymas buvo nesėkmingas dviem atvejais – po vieną atvejį abiejose grupėse.IšvadosŠiuo metu nėra tobulo gydymo tų pacientų, kuriems prostatos vėžys recidyvavo po spindulinio gydymo. Tokiais atvejais reikalingi unikalūs sprendimai. Mūsų nedidelė pirmoji patirtis rodo, jog gelbstinčioji krioterapija ir brachiterapija – tinkami metodaigydyti pacientams, kuriems recidyvavo prostatos vėžys po spindulinės terapijos.Reikšminiai žodžiai: prostatos vėžys, prostatos vėžio recidyvai, gelbstintis gydymas.
APA, Harvard, Vancouver, ISO, and other styles
4

Kucuk, Omer, Fazlul H. Sarkar, Wael Sakr, Fred Khachik, Zora Djuric, Mousumi Banerjee, Michael N. Pollak, John S. Bertram, and David P. Wood. "Lycopene in the treatment of prostate cancer." Pure and Applied Chemistry 74, no. 8 (January 1, 2002): 1443–50. http://dx.doi.org/10.1351/pac200274081443.

Full text
Abstract:
Dietary intake of lycopene is associated with reduced risk of prostate cancer (PCa). We conducted a clinical trial in men with prostate cancer to investigate the biological and clinical effects of lycopene supplementation. Twenty-six men with prostate cancer were randomly assigned to receive a lycopene supplement or no supplement for three weeks before radical prostatectomy. Subjects in the intervention group (n = 15) were instructed to take a tomato oleoresin extract soft gel capsule (Lyc-O-Mato®, LycoRed Company, Beer Sheva, Israel) containing 15 mg lycopene, 1.5 mg phytoene, 1.5 mg phytofluene, and 5 mg tocopherol twice daily with meals. Prostatectomy specimens were evaluated for pathologic stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepithelial neoplasia (HGPIN). Biomarkers of cell proliferation and apoptosis were assessed by Western blot analysis in benign and cancerous tissue samples obtained from the prostatectomy specimens. Oxidative stress was assessed by measuring the peripheral blood lymphocyte DNA oxidation product 5-hydroxymethyl-deoxyuridine (5-OH-mdU). Plasma levels of lycopene, insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and prostate-specific antigen (PSA) were measured at baseline and after three weeks of study period. After the intervention, more men in the intervention group had smaller (<4 cc) tumors, organ-confined disease without involvement of surgical margins or extra-prostatic tissues, and focal involvement of the prostate with HGPIN compared to the control group. Mean plasma PSA levels were lower in the intervention group compared to the control group. This pilot study suggests that a tomato extract containing lycopene and other tomato carotenoids and phytochemicals may have a potential role in the treatment of prostate cancer. Larger clinical trials are necessary to definitively address potential uses of lycopene or tomato extract in the prevention or treatment of prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
5

deKernion, Jean B. "IL-2 Progress in Research and Treatment of Prostate Cancer." Japanese Journal of Urology 98, no. 2 (2007): 54. http://dx.doi.org/10.5980/jpnjurol.98.54.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Xu, Huan, Yanbo Chen, Meng Gu, Chong Liu, Qi Chen, Ming Zhan, and Zhong Wang. "Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer." Metabolites 11, no. 11 (November 9, 2021): 765. http://dx.doi.org/10.3390/metabo11110765.

Full text
Abstract:
Prostate cancer (PCa) is a carcinoma in which fatty acids are abundant. Fatty acid metabolism is rewired during PCa development. Although PCa can be treated with hormone therapy, after prolonged treatment, castration-resistant prostate cancer can develop and can lead to increased mortality. Changes to fatty acid metabolism occur systemically and locally in prostate cancer patients, and understanding these changes may lead to individualized treatments, especially in advanced, castration-resistant prostate cancers. The fatty acid metabolic changes are not merely reflective of oncogenic activity, but in many cases, these represent a critical factor in cancer initiation and development. In this review, we analyzed the literature regarding systemic changes to fatty acid metabolism in PCa patients and how these changes relate to obesity, diet, circulating metabolites, and peri-prostatic adipose tissue. We also analyzed cellular fatty acid metabolism in prostate cancer, including fatty acid uptake, de novo lipogenesis, fatty acid elongation, and oxidation. This review broadens our view of fatty acid switches in PCa and presents potential candidates for PCa treatment and diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
7

Dehn, Tom. "Prostate Cancer Treatment." Annals of The Royal College of Surgeons of England 88, no. 5 (September 2006): 439. http://dx.doi.org/10.1308/003588406x117133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Markovic, B., Z. Markovic, J. Filimonovic, and J. Hadzi-Djokic. "New generation urethral stents in treatment bladder outlet obstruction caused by prostate cancer." Acta chirurgica Iugoslavica 52, no. 4 (2005): 89–92. http://dx.doi.org/10.2298/aci0504089m.

Full text
Abstract:
Our clinical trial included until now, 22 patients in whom new generation urethral stent named Allium, were inserted due to bladder outlet obstruction caused in 7 patients (pt) with benign prostae hyperplasia, in 13 pt with bulbar urethral stricture of different ethiology and in 2 pt with prostate cancer. Allium prostatic stents, designed by Daniel Yachia differs in some crucial characteristics from previously used stents: they are covered for the first time in urethra stenting history, without relatively low radiation force and because of that nonirritative. the indications, contraindications and preliminary results in this study are discussed concerning the patients with cancer of the prostate.
APA, Harvard, Vancouver, ISO, and other styles
9

Bartzatt, Ronald. "Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines." Current Topics in Medicinal Chemistry 20, no. 10 (May 19, 2020): 847–54. http://dx.doi.org/10.2174/1568026620666200224100730.

Full text
Abstract:
Cancer of the prostate are cancers in which most incidences are slow-growing, and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone- refractory prostate cancer is making progress, for almost all men with metastases will proceed to hormone-refractory prostate cancer. Smoking cigarettes along with the presence of prostate cancer has been shown to cause a higher risk of mortality in prostate cancer. The serious outcome of incontinence and erectile dysfunction result from the cancer treatment of surgery and radiation, particularly for prostate- specific antigen detected cancers that will not cause morbidity or mortality. Families of patients, as well as patients, are profoundly affected following the diagnosis of prostate cancer. Poor communication between spouses during prostate cancer increases the risk for poor adjustment to prostate cancer. The use of serum prostate-specific antigen to screen for prostate cancer has led to a greater detection, in its early stage, of this cancer. Prostate cancer is the most common malignancy in American men, accounting for more than 29% of all diagnosed cancers and about 13% of all cancer deaths. A shortened course of hormonal therapy with docetaxel following radical prostatectomy (or radiation therapy) for high-risk prostate cancer has been shown to be both safe and feasible. Patients treated with docetaxel-estramustine had a prostate-specific antigen response decline of at least 50%. Cancer vaccines are an immune-based cancer treatment that may provide the promise of a non-toxic but efficacious therapeutic alternative for cancer patients. Further studies will elucidate improved methods of detection and treatment.
APA, Harvard, Vancouver, ISO, and other styles
10

Krušlin, Božo, Lucija Škara, Tonći Vodopić, Borna Vrhovec, Jure Murgić, Goran Štimac, Ana Fröbe, Cvjetko Lež, Monika Ulamec, and Koraljka Gall-Trošelj. "Genetics of Prostate Carcinoma." Acta Medica Academica 50, no. 1 (May 26, 2021): 71. http://dx.doi.org/10.5644/ama2006-124.327.

Full text
Abstract:
<p>The aim of this review is to provide a brief overview of some current approaches regarding diagnostics, pathologic features, treatment, and genetics of prostate carcinoma (PCa). Prostate carcinoma is the most common visceral tumor and the second most common cancer-related cause of death in males. Clinical outcomes for patients with localized prostate cancer are excellent, but despite advances in prostate cancer treatments, castrate-resistant prostate cancer and metastatic prostate cancer patients have a poor prognosis. Advanced large-scale genomic studies revealed a large number of genetic alterations in prostate cancer. The meaning of these alterations needs to be validated in the specific prostate cancer molecular subtype context. Along these lines, there is a critical need for establishing genetically engineered mouse models, which would include speckle type BTB/POZ protein and isocitrate Dehydrogenase (NADP (+)) 1 mutant, as well as androgen receptor neuroendocrine subtypes of prostate cancer. Another urgent need is developing highly metastatic prostate cancer models, as only up to 17% of available models dis- play bone metastases and exhibit a less typical neuroendocrine prostate cancer or sarcomatoid carcinoma. Moreover, androgen deprivation and relapse should be mimicked in the genetically engineered mouse models, as androgen independence may yield a better model for metastatic castrate-resistant prostate cancer. The development of such refined animal models should be guid- ed by comparative genomics of primary versus corresponding metastatic tumors. Such an approach will have the potential to illuminate the key genetic events associated with specific molecular prostate cancer subsets and indicate directions for effective therapy.</p><p><strong>Conclusion</strong>. Despite excellent results in the treatment of localized prostatic carcinoma, castrate-resistant prostate can- cer and metastatic prostate cancer have a poor prognosis. Advanced large-scale genomic studies revealed a large number of ge- netic alterations in PCa. Experimental models of prostate carcinoma in genetically modified mice could provide new data about the genetic changes in such cancers and help in developing better animal models for treatment resistant prostate carcinomas.</p>
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Prostate – Cancer – Treatment"

1

Wirth, Manfred P., and Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133890.

Full text
Abstract:
The guidelines for the curative treatment of prostate cancer presented by the German Society of Urology are discussed. They are based on the current knowledge of the outcomes of surgical and radiotherapeutic treatment for prostate cancer. Radical prostatectomy is recommended as the first-line treatment for organ-confined prostate cancer in patients with an individual life expectancy of at least 10 years. Radiotherapy can be considered as an alternative treatment modality, although current knowledge does not allow a definite assessment of the relative value of radiotherapy compared to radical prostatectomy. Locally advanced cT3 prostate cancer is overstaged in about 20% and curative treatment is possible in selected cases. Guidelines represent rules based on the available evidence. This implies that exceptions must be made whenever appropriate and that guidelines have to be reviewed regularly as new information becomes available
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
2

Wirth, Manfred P., and Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer." Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27546.

Full text
Abstract:
The guidelines for the curative treatment of prostate cancer presented by the German Society of Urology are discussed. They are based on the current knowledge of the outcomes of surgical and radiotherapeutic treatment for prostate cancer. Radical prostatectomy is recommended as the first-line treatment for organ-confined prostate cancer in patients with an individual life expectancy of at least 10 years. Radiotherapy can be considered as an alternative treatment modality, although current knowledge does not allow a definite assessment of the relative value of radiotherapy compared to radical prostatectomy. Locally advanced cT3 prostate cancer is overstaged in about 20% and curative treatment is possible in selected cases. Guidelines represent rules based on the available evidence. This implies that exceptions must be made whenever appropriate and that guidelines have to be reviewed regularly as new information becomes available.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
3

Wirth, Manfred P., and Michael Fröhner. "Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133551.

Full text
Abstract:
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51–0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
4

Wirth, Manfred P., and Michael Fröhner. "Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program." Karger, 2003. https://tud.qucosa.de/id/qucosa%3A27515.

Full text
Abstract:
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51–0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
5

Knight, Kellie Ann. "Daily Image Guided Radiation Therapy for Prostate Cancer: An assessment of treatment plan reproducibility." Thesis, The University of Sydney, 2006. http://hdl.handle.net/2123/1628.

Full text
Abstract:
It is well documented that for prostate cancer patients undergoing radiation therapy there is a correlation between target volume displacement and changes in bladder and rectal volumes. However, these studies have used a methodology that has captured only a subset of all treatment positions. This research used daily Computer Tomography (CT) imaging to comprehensively assess organ volumes, organ motion and their effect on dose, something that has never been performed previously, thus adding considerably to the understanding of the topic. Daily CT images were obtained using a Siemens Primus Linear Accelerator equipped with an in-room Somatom CT unit in the accelerator suite, marketed as ‘Primatom’, to accurately position the patient prior to treatment delivery. The internal structures of interest were contoured on the planning workstation by the investigator. The daily volume and location of the organs were derived from the computer to assess and analyse internal organ motion. The planned dose distribution was then imported onto the treatment CT datasets and used to compare the planned dose to i) the actual isocentre, where the isocentre was actually placed for that fraction, ii) the uncorrected isocentre, by un-doing any on-line corrections performed by the treatment staff prior to treatment delivery, and iii) the future isocentre, by placing the isocentre relative to internal organ motion on a daily basis. The results of this study did not confirm a statistically significant decrease in rectum volumes over time (hypothesis 1), however large fluctuations in bladder volume were confirmed (hypothesis 2). Internal organ motion for the rectum and bladder was demonstrated to be related to organ filling. Ideal planning volumes for these organs have been reported to minimise systematic and random uncertainty in the treatment volumes. An observed decrease in prostate volume over time, a systematic uncertainty in the location of the prostate at the time of the planning CT scan and a significant relationship between prostate centre of volume and rectum and bladder volumes has resulted in a recommendation that patients should be re-scanned during treatment to ensure appropriate clinical target volume coverage. A significant relationship between rectal and bladder volumes and the dose delivered to these organs was found (hypothesis 3). The dose delivered to the planning target volume was not related to the rectal or bladder volumes, although it was related to the motion of these organs. Despite these results only minimal effects on the dose delivered to any of the three isocentres occurred, indicating that the planned dose was accurately delivered using the methodology presented here (hypothesis 4). However the results do indicate that the patient preparation instructions need to be improved if margins are to be reduced in the future. It is unrealistic to assume that Image Guided Radiation Therapy will ever become routine practice due to infrastructure costs and time limitations. This research will inform radiation therapy centres of the variables associated with prostate cancer treatment on a daily basis, something that has never before been realistically achievable. As a result centres will be able to devise protocols to improve treatment outcomes.
APA, Harvard, Vancouver, ISO, and other styles
6

Knight, Kellie Ann. "Daily Image Guided Radiation Therapy for Prostate Cancer: An assessment of treatment plan reproducibility." University of Sydney, 2006. http://hdl.handle.net/2123/1628.

Full text
Abstract:
Doctor of Health Science
It is well documented that for prostate cancer patients undergoing radiation therapy there is a correlation between target volume displacement and changes in bladder and rectal volumes. However, these studies have used a methodology that has captured only a subset of all treatment positions. This research used daily Computer Tomography (CT) imaging to comprehensively assess organ volumes, organ motion and their effect on dose, something that has never been performed previously, thus adding considerably to the understanding of the topic. Daily CT images were obtained using a Siemens Primus Linear Accelerator equipped with an in-room Somatom CT unit in the accelerator suite, marketed as ‘Primatom’, to accurately position the patient prior to treatment delivery. The internal structures of interest were contoured on the planning workstation by the investigator. The daily volume and location of the organs were derived from the computer to assess and analyse internal organ motion. The planned dose distribution was then imported onto the treatment CT datasets and used to compare the planned dose to i) the actual isocentre, where the isocentre was actually placed for that fraction, ii) the uncorrected isocentre, by un-doing any on-line corrections performed by the treatment staff prior to treatment delivery, and iii) the future isocentre, by placing the isocentre relative to internal organ motion on a daily basis. The results of this study did not confirm a statistically significant decrease in rectum volumes over time (hypothesis 1), however large fluctuations in bladder volume were confirmed (hypothesis 2). Internal organ motion for the rectum and bladder was demonstrated to be related to organ filling. Ideal planning volumes for these organs have been reported to minimise systematic and random uncertainty in the treatment volumes. An observed decrease in prostate volume over time, a systematic uncertainty in the location of the prostate at the time of the planning CT scan and a significant relationship between prostate centre of volume and rectum and bladder volumes has resulted in a recommendation that patients should be re-scanned during treatment to ensure appropriate clinical target volume coverage. A significant relationship between rectal and bladder volumes and the dose delivered to these organs was found (hypothesis 3). The dose delivered to the planning target volume was not related to the rectal or bladder volumes, although it was related to the motion of these organs. Despite these results only minimal effects on the dose delivered to any of the three isocentres occurred, indicating that the planned dose was accurately delivered using the methodology presented here (hypothesis 4). However the results do indicate that the patient preparation instructions need to be improved if margins are to be reduced in the future. It is unrealistic to assume that Image Guided Radiation Therapy will ever become routine practice due to infrastructure costs and time limitations. This research will inform radiation therapy centres of the variables associated with prostate cancer treatment on a daily basis, something that has never before been realistically achievable. As a result centres will be able to devise protocols to improve treatment outcomes.
APA, Harvard, Vancouver, ISO, and other styles
7

Wirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133839.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Karger, 2002. https://tud.qucosa.de/id/qucosa%3A27540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Elshafae, Said Mohammed Abbas. "Pathogenesis and Treatment of Canine Prostate Cancer." The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1492081831172341.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Martinez, De Pinillos Bayona A. "Light-based therapies in prostate cancer treatment." Thesis, University College London (University of London), 2016. http://discovery.ucl.ac.uk/1532467/.

Full text
Abstract:
Photodynamic Therapy (PDT) and Photochemical Internalisation (PCI) are both light-based therapies which can be used for the focal treatment of cancer. Both PDT and PCI require the combination of photosensitisers, light and molecular oxygen to induce photooxidative reactions that damage biomolecules. However, while PDT employs a photosensitiser as the sole therapeutic agent, PCI combines low-dose PDT with another therapeutic agent to enable the improved delivery of this agent to its intended subcellular targets. The overall aim of this study was to investigate PDT and PCI for prostate cancer in both in vitro and in vivo tumour models. In the PCI procedures, the ribosome inactivating protein type 1 saporin was used as a model chemotherapy agent. We have concluded an enhancement in cell killing in prostate carcinoma cells after PCI compared to PDT in 2-dimensional models, i.e. 80% cell death, compared to 32% killing after PDT. Similar observations resulted from qualitative observations in the 3-dimensional model. Moreover, conjugation of a photosensitiser to cell penetrating peptides (TAT or Antp), resulted in a similar difference in cytotoxicity after PCI and PDT using lower concentrations of the conjugates - 76% and 14% respectively. These data confirm the synergistic effect of drug and photosensitiser in PCI. Three different clinically relevant photosensitisers were used in vivo in a subcutaneous rat model. Vascular-targeted PDT resulted in the most efficient treatment, and photosensitisers targeting a cellular effect, showed a better outcome with shorter drug-light intervals. The analysis of tumour samples through immunohistochemistry and molecular analysis revealed an innate inflammatory response that led to an adaptive immune response. A highly suppressive tumour microenvironment was suggested by the infiltration of regulatory T cells (FoxP3+), up-regulation of PD-L1 and down-regulation of cytolytic proteins (i.e. Perforin). Moreover, the beneficial effect of using immunoadjuvants (cyclophosphamide) was investigated. Light based therapies could play an important role in prostate cancer treatment both eradicating tumours and generating long-term immune protection against secondary tumour deposits.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Prostate – Cancer – Treatment"

1

I, Patel Manish, ed. Prostate cancer. 7th ed. Abingdon: Health Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Prostate cancer. Paris: Health Publications, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Systemic treatment of prostate cancer. Oxford: Oxford University Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1953-, McCormack Michael, ed. Understanding prostate cancer. Montréal: Rogers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Feneley, Mark R., and Heather A. Payne. Prostate cancer. Oxford: Clinical Pub., 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

National Center for Biotechnology Information (États-Unis). Prostate cancer: Diagnosis and treatment. Cardiff, Wales: National Collaborating Centre for Cancer, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

ABC of prostate cancer. Chichester, West Sussex, UK: Blackwell Pub., 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lynch, Patricia D. Cancer of the prostate. [Bethesda, Md.]: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

K, Brawer Michael, and Denis Louis J, eds. Prostate cancer. 2nd ed. Oxford: Health Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kirby, R. S. Prostate cancer. 2nd ed. London: Mosby, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Prostate – Cancer – Treatment"

1

Wilding, G., and M. E. Lippman. "Prostate Cancer." In New Directions in Cancer Treatment, 501–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83405-9_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gadzinski, Adam J., and Matthew R. Cooperberg. "Prostate Cancer Markers." In Cancer Treatment and Research, 55–86. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93339-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Prezioso, Domenico, Raffaele Galasso, Mario Di Martino, and Gennaro Iapicca. "Prostate Cancer Treatment and Quality of Life." In Prostate Cancer, 251–65. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-40901-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dean, Lucas W., and Karim A. Touijer. "Evaluation and Treatment for High-Risk Prostate Cancer." In Prostate Cancer, 135–56. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-78646-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Press, Benjamin H., Marc A. Bjurlin, and Samir S. Taneja. "Evaluation and Treatment for Older Men with Elevated PSA." In Prostate Cancer, 21–41. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-78646-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Goonewardene, Sanchia S., and Raj Persad. "Prostate Cancer and Radical Treatment." In Prostate Cancer Survivorship, 9–11. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-65358-7_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Johnson, David Y., Shilpi Wadhwa, and Frank E. Johnson. "Prostate Carcinoma." In Patient Surveillance After Cancer Treatment, 399–401. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-60327-969-7_80.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nabhan, Chadi, and Raymond Bergan. "Chemoprevention in Prostate Cancer." In Cancer Treatment and Research, 103–36. Boston, MA: Springer US, 2001. http://dx.doi.org/10.1007/978-1-4615-1657-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Brendler, Charles B. "Isoenzymes in prostate cancer." In Cancer Treatment and Research, 1–18. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2033-3_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Georges, Cletus R., and Kevin T. McVary. "Rehabilitation of prostate cancer." In Cancer Treatment and Research, 135–60. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-5003-7_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Prostate – Cancer – Treatment"

1

Tse, Zion Tsz Ho, Sheng Xu, Alexander Squires, Yue Chen, Reza Seifabadi, Harsh Agrawal, Peter Pinto, Peter Choyke, and Bradford Wood. "Robot for MRI-Guided Prostate Cancer Focal Laser Ablation." In 2017 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/dmd2017-3511.

Full text
Abstract:
Prostate cancer is the most common cancer among males, leading to approximately 27,000 deaths in the United States [1]. Focal laser ablation (FLA) has been shown to be a promising approach for prostate cancer treatment with the advantage of efficiently ablating the cancer cells while inflicting less damage on the surrounding tissues. In current FLA procedures, a rigid template — with holes spacing of 5mm — guides the FLA catheter to the target position. Drawbacks of the conventional approach for catheter targeting are 1) limited degrees of freedom (DoF) and 2) a low insertion resolution. In addition, the targeting capability of the rigid template is compromised when the pubic arch or nerve bundles intersect the catheter trajectory. We hypothesized that a compact design of an MRI-conditional robot with two active planar DoFs, one passive rotation DoF, and remote catheter insertion capacities could enhance the clinical workflow required for MRI-guided FLA prostate procedures.
APA, Harvard, Vancouver, ISO, and other styles
2

Herrera-Rodrı́guez, M. R. "Brachytherapy treatment planning algorithm applied to prostate cancer." In The fourth mexican symposium on medical physics. AIP, 2000. http://dx.doi.org/10.1063/1.1328967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ernzen, Kyle J., Subramanyam Dasari, and Gnanasekar Munirathinam. "Abstract 2873: Targeting RAGE for prostate cancer treatment." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2873.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sherar, M. D., L. Chin, M. C. Kolios, and A. S. Gladman. "The Effect of Heat Induced Changes in Microwave Tissue Properties on Microwave Thermal Therapy for Prostate Cancer." In ASME 1999 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1999. http://dx.doi.org/10.1115/imece1999-0590.

Full text
Abstract:
Abstract The delivery of heat to the prostate using microwave antennas is being investigated as an experimental treatment for prostate cancer. Tissue temperatures can be calculated by solving the bioheat equation with the volumetric power deposition of the antenna as an input. This heating pattern is expected to change during heating due to changes in the electrical properties of the prostate. We have measured the microwave properties of rat prostate as a function of temperature and time and applied these parameters to the solution of the bioheat equation. We describe the nature of the changes in prostate tissue properties with heating. In addition, we present simulations of microwave heating in prostate tissue which illustrate the significance of including heat induced changes in tissue properties for this thermal therapy application. The prostate tissue measurements were performed using a loaded coaxial cable technique where the tissue sample could be rapidly heated as measurements were taken. Prostate treatment simulations were performed using a finite element approach to the bioheat equation.
APA, Harvard, Vancouver, ISO, and other styles
5

Kannan, Vaishnavi, Duwayne L. Willett, Pamela J. Goad, Claus G. Roehrborn, and Mujeeb A. Basit. "Mapping the Treatment Journey for Patients with Prostate Cancer." In 2018 IEEE International Conference on Healthcare Informatics (ICHI). IEEE, 2018. http://dx.doi.org/10.1109/ichi.2018.00063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Venier, Natalie A., Alexandra J. Colquhoun, Andrew Loblaw, Neil E. Fleshner, Laurence H. Klotz, and Vasundara Venkateswaran. "Abstract 1449: Spicing up radiation treatment for prostate cancer." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1449.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ng Choong Kheng, Ng Wan Sing, L. Phee, and C. Cheng. "A hifu robot for transperineal treatment of prostate cancer." In ICARV 2002: The Seventh International Conference on Control, Automation, Robotics and Vision. IEEE, 2002. http://dx.doi.org/10.1109/icarcv.2002.1238485.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mitchell, Melanie, James A. Tanyi, and Arthur Y. Hung. "Automatic Segmentation of the Prostate Using a Genetic Algorithm for Prostate Cancer Treatment Planning." In 2010 International Conference on Machine Learning and Applications (ICMLA). IEEE, 2010. http://dx.doi.org/10.1109/icmla.2010.115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

McNeel, Douglas, Marcella Fasso, Laura Johnson, Ed Lemmens, Bill Hanson, Pete Lauer, Steven Bodovitz, Charles Drake, and Dirk G. Brockstedt. "Abstract 2837: Combined targeting of antigens expressed in prostate cancer and prostate stem cells using Listeria-based cancer vaccines for the treatment of prostate cancer." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2837.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bhowmick, Sankha, and John C. Bischof. "Supraphysiological Thermal Injury in Dunning AT-1 Prostate Tumor Cells." In ASME 1998 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/imece1998-0798.

Full text
Abstract:
Abstract Supraphysiological temperatures are generated by radiofrequency and microwave probes used for the treatment of prostate cancer (Montrosi et al., 1992) and benign prostatic hyperplasia (Larson et al., 1996). A quantitative understanding of the cellular mechanisms of tissue destruction due to these supraphysiological temperatures(&gt; 40°C) is necessary for optimal application of clinical therapeutic protocols on the prostate and other tissue systems. A multitude of biophysical and biochemical events take place at the cellular level due to thermal stress (Cravalho et al., 1992). Some of the events include hyperpermeability of the membrane, denaturation of proteins, changes in cytoskeleton, alteration of intracellular ionic concentration and nuclear degradation. This study quantifies membrane injury by measuring the dynamics of vital dye leakage (Calcein) and Propidium Iodide (PI) uptake in the AT-1 Dunning rat prostate tumor cell line. Membrane injury (using these two dyes) is compared to the clonogenicity of these cells after comparable thermal insult. An Arrhenius damage model has been constructed for each of these assays based on a damage parameter to obtain the activation Energy (E) and frequency factor (A), which may prove useful in obtaining insight into the mechanisms of damage associated with thermal injury.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Prostate – Cancer – Treatment"

1

Gmeiner, William H. Metallated DNA Aptamers for Prostate Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, March 2013. http://dx.doi.org/10.21236/ada578778.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gmeiner, William. Metallated DNA Aptamers For Prostate Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, March 2012. http://dx.doi.org/10.21236/ada559240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Tiezhi. On-line Adaptive Radiation Treatment of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2008. http://dx.doi.org/10.21236/ada491155.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Tiezhi. On-line Adaptive Radiation Treatment of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2009. http://dx.doi.org/10.21236/ada500943.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Heidari, Afshin, Aida Kazemi, Parisa Najjari, Kamran Dalvandi, Hamidreza Sadeghsalehi, Parinaz Onikzeh, and Hadi Zamanian. Comparing Urinary and Sexual Complications of Robot-Assisted Radical Prostatectomy and Laparoscopic Radical Prostatectomy in Prostate Cancer: a Systematic Review and Meta-Analysis Protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2021. http://dx.doi.org/10.37766/inplasy2021.10.0068.

Full text
Abstract:
Review question / Objective: The aims of this study are: 1. To compare urinary complications of robot-assisted radical prostatectomy(RARP) and laparoscopic radical prostatectomy(LRP) in patients with prostate cancer; 2. To compare sexual complications of RARP and LRP in patients with prostate cancer. Condition being studied: Prostate cancer is one of the most prevalent types of cancer; according to 2018 statistics, prostate cancer was responsible for 7.1% of all cancer in men. The primary intervention in such patients is radical prostatectomy surgery (RP), which could be performed in different methods in patients that cancer has not spread beyond the prostate gland or has not spread much. One of the most common types of RP is laparoscopic radical prostatectomy. There are several techniques for performing RP; two are Conventional Laparoscopic Radical Prostatectomy (LRP) and Robot-Assisted Radical Prostatectomy (RARP). Sexual and urinary difficulties can occur in prostate cancer patients due to cancer itself or the treatment. Like any treatment option and surgery, radical prostatectomy can carry risks, like urinary(e.g., incontinency) and sexual complications(e.g., Impotence). In this review, we compared urinary and sexual complications of LRP and RARP.
APA, Harvard, Vancouver, ISO, and other styles
6

Stadler, Walter M. Androgen Replacement as Treatment for Hormone Refractory Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2005. http://dx.doi.org/10.21236/ada442980.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Janowsky, Jeri. Exploration of Prostate Cancer Treatment Induced Neurotoxicity with Neuroimaging. Fort Belvoir, VA: Defense Technical Information Center, May 2008. http://dx.doi.org/10.21236/ada484214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Baldassare, Joseph J. Targeted Zinc Delivery: A Novel Treatment for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2008. http://dx.doi.org/10.21236/ada486936.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rodeck, Ulrich. Reducing Toxicity of Radiation Treatment of Advanced Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada611579.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rodeck, Ulrich. Reducing Toxicity of Radiation Treatment of Advanced Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada594169.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Prostate – Cancer – Treatment' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography